

**Priority question for written answer P-003518/2023  
to the Commission**  
Rule 138  
**Ivan Vilibor Sinčić (NI)**

**Subject:** Monitoring long-term effects of COVID-19 vaccination on EU citizens

In view of the Commission's statement<sup>1</sup> on the number of COVID-19 vaccine doses delivered, I would be grateful for clarification of the following points:

1. Who exactly is in charge of monitoring the long-term health impact of COVID-19 vaccination on EU citizens and what are the scientific qualifications and expertise of the people and/or agencies, institutes or health institutions in charge of this monitoring, given that concerns is a specific genetic product that was administered via an 'emergency' procedure without standard safety measures based on clinical trials?
2. What precautionary measures has the Commission and/or the European Medicines Agency (EMA) adopted apart from the currently implemented regulatory procedures in relation to possible serious health effects of a novel product that is regulated as a genetic product rather than a vaccine and in view of its administration to a large population group in the EU?

Submitted: 30.11.2023

---

<sup>1</sup> Parliamentary question | Answer for question P-002470/23 | P-002470/2023(ASW) | European Parliament (europa.eu)